Rate Video

ARUK 2019 | The heterogeneity of Alzheimer’s disease

Philip Scheltens • 19 Mar 2019

Alzheimer’s Disease Dementia

Philip Scheltens, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, speaks at the Alzheimer’s Research UK (ARUK) Conference 2019, held in Harrogate, UK. He discusses the heterogeneity of Alzheimer’s disease and how this may impact drug trials.

Cerebrospinal fluid (CSF) and imaging biomarkers for the differential diagnosis of dementia

Philip Scheltens • 24 Jun 2017

Alzheimer's early diagnosis: challenges and benefits

Philip Scheltens • 19 Mar 2019

Declining dementia incidence

Philip Scheltens • 29 May 2016

Outcome measures in dementia studies

Philip Scheltens • 25 Jun 2017

Related Videos

Hearing loss and dementia: peripheral vs central aspects

Dona Jayakody • 17 Sep 2023

Blood-based biomarkers for treatment monitoring in Alzheimer’s disease

Suzanne Schindler • 19 Aug 2023

The Phase III LUCIDITY trial: a tau aggregation inhibitor in patients with Alzheimer’s disease

Sonya Miller • 17 Aug 2023

Time gap between amyloid- and tau-PET positivity in preclinical disease

Alexis Moscoso • 7 Aug 2023